This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Radiopharmaceuticals Market

Radiopharmaceuticals uptake receiving traction amid Increasing Patient awareness, disease-targeted cancer therapy, and use of molecular imaging

Radiopharmaceuticals Market by Radioisotope Type, Application, Source, End-user, Region & Forecast 2022 to 2032

Radiopharmaceuticals Market Snapshot (2022 to 2032)

[190 Pages Report] According to Future Market Insights (FMI), the radiopharmaceuticals market would be worth US$ 6.2 Billion in 2022. During the forecast period ranging from 2022 to 2032, radiopharmaceuticals uptake is anticipated to flourish at a value CAGR of 4.3% to reach US$ 9.5 Billion.

Because of the rising frequency of cancer cases and the expansion of the healthcare industry in the United States and Canada, North America will account for more than 47% of the worldwide market.

According to Future Market Insights, notable participants include Siemens AG, General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler. In the worldwide radiopharmaceuticals market, the top companies account for over 90% of revenue.

Data Points 

 Key Statistics 

Radiopharmaceuticals Market Value 2022 

 US$ 6.2 Billion

Radiopharmaceuticals Market Projected Value (2032) 

 US$ 9.5 Billion 

Radiopharmaceuticals Market CAGR (2022 to 2032) 

 4.3% 

Customize this Report

Let us know your requirement to get
100% FREE customization

Radiopharmaceuticals Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)

The global demand for radiopharmaceuticals projected to increase at a CAGR of 4.3% during the forecast period between 2022 and 2032, reaching a total of US$ 9.5 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 3.8%.

Improving radio-therapeutic penetration is predicted to be the primary driver of the radiopharmaceuticals market. Radiopharmaceuticals are rapidly being utilized to diagnose and treat a variety of ailments, including cancer, cardiovascular disease, and neurological problems. Radiopharmaceuticals are widely utilized in the treatment of certain disorders due to the properties of radioactive decay and the possibility of focused therapeutic irradiation. However, the unusual outbreak of COVID-19 hampered market expansion.

Radioisotope production has been ceased worldwide, as have research efforts. The worldwide market value fell as a result of disruptions in the demand and supply chains. The rapid use of sophisticated nuclear imaging technologies such as SPECT and Positron Emission Tomography (PET) will considerably contribute to market development. Radiopharmaceuticals market expansion is being aided by increased research and development from key players.

GE Healthcare, for example, provided cloud and IT-based solutions and apps to link medical imaging with analytics and insights. The growing clinical uses of radiopharmaceuticals in cancer, cardiology, endocrinology, and neurology are boosting market growth.

Which Drivers underpin Radiopharmaceuticals Industry Expansion?

Developing Centralized Pharmacies to Support Growth

There is a dearth of codified good manufacturing practice (GMP) requirements in the radiopharmaceutical sector, as well as rigid laws controlling the use of radiopharmaceuticals. To solve quality assurance difficulties, nuclear medicine practitioners are advocating for the establishment of centralized radio-pharmacies.

This is because administrators and lawmakers are becoming increasingly interested in radiopharmaceutical, Positron Emission Tomography (PET), and clinical trial laws. A centralized radio pharmacy concept provides various benefits to patients and governing authorities, including the capacity to dispense patient-specific prescriptions and supply requested items from all sources and services accessible. These activities are projected to enhance market expansion throughout the forecast period.

Increasing Disease Prevalence is Accelerating the Market Growth

One of the prominent drivers fueling market expansion is the rising prevalence of acute and chronic illnesses such as cancer throughout the world as a result of numerous causes. Radiopharmaceuticals allow for the detection of tumor cells in organs or across the body. Cancer is the world's second largest cause of death.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors are limiting the Growth of Radiopharmaceuticals Market?

Expensive Costs Connected with R&D Capabilities to Impede the Market Growth

Expensive costs connected with R&D capabilities, inadequate infrastructure facilities, short half-life of radiopharmaceuticals, high equipment prices, and a lack of awareness in backward economies are predicted to stymie market expansion.

In addition, a lack of favourable reimbursement scenarios and technology penetration in developing economies, hospital budget cuts, particularly during pandemics, and a lack of suitable infrastructure in low- and middle-income countries are expected to pose challenges to the market during the forecast period.

Country-wise Insights

Will North America Continue Dominance in the Global Radiopharmaceuticals Market?

Increased Frequency of Cancer and Cardiovascular Illnesses to Fuel the Market Growth

Because of its large number of healthcare facilities, expanding overweight population, large patient population suffering from chronic diseases such as cancer, cardiovascular disorders, and strokes, and rising number of research activities, North America dominates the radiopharmaceuticals market.

The increased frequency of cancer and cardiovascular illnesses in the United States is driving the growth of the radiopharmaceuticals market. Nuclear medicine sales have increased due to an ageing population and bad lifestyle choices, which have resulted in an increase in cancer and obesity cases. Adoption of innovative radioisotope manufacturing methods to treat these disorders is expected to boost the country's radiopharmaceutical growth. The American Heart Association estimates that 17.3 million people die each year as a result of cardiovascular disease.

Radiopharmaceuticals provide radiologists an advantage in the treatment of various disorders. Targeted medicines and sophisticated technologies incorporated in cyclotrons for the treatment of cardiovascular disease and cancer will boost radiopharmaceutical demand in the United States. Based on the above, the United States will dominate the North American radiopharmaceuticals market throughout the projection period, accounting for more than 45% of market share.

Where does the growth of Radiopharmaceuticals Market in Asia Pacific Excluding Japan stand?

Expansion of the Healthcare Industry to fuel Market Growth

Product launches, acquisitions, distribution agreements, collaborations, and regional expansion by local firms, notably in India, are projected to boost the radiopharmaceuticals market in the Asia Pacific Excluding Japan.

The expansion of the healthcare industry and the adoption of improved technologies are the primary drivers of the radiopharmaceuticals market in India. Along with this, the country's high cancer prevalence has boosted the use of targeted medicines and enhanced radioisotope manufacturing.

The growing inclination for non-invasive medicines in India, as well as the great effectiveness provided by radiopharmaceuticals, is the primary reasons why radiopharmaceuticals are booming. Government and commercial healthcare organizations are expanding financing and R&D efforts to produce efficient tailored medicines with fewer adverse effects.

The incorporation of cutting-edge technology in the development of sophisticated radiotracers for the treatment of cancer and cardiovascular disease is assisting in the expansion. Several research projects launched by the National Cancer Institute have increased the manufacturing and use of radioisotopes for cancer therapy in India.

Why is the need for radiopharmaceuticals increasing in the United Kingdom?

Rising Incidences of Cancer in the Region to Accelerate Market

The United Kingdom is likely to be a major country in Europe, accounting for the largest proportion of the European radiopharmaceuticals market. Cancer is becoming more common in the United Kingdom resulting in increased production of radioisotopes for enhanced molecular imaging and cancer therapy treatments Radiopharmaceutical advantages, such as high effectiveness and non-invasive external monitoring, have encouraged radioisotope manufacturing.

According to a Cancer Research United Kingdom estimate, roughly 367,167 cancer cases are diagnosed in the United Kingdom. Every year, around 166,000 cancer deaths are documented. Rising scenarios like this are expected to promote the expansion of the country's radiopharmaceuticals industry. Expansion of healthcare infrastructure and more research on non-invasive targeted medicines to minimise the load would greatly increase radiopharmaceutical demand in the United Kingdom. The growing interest of healthcare professionals, administrators, and lawmakers in radiopharmaceutical, positron emission tomography, and clinical trial standards will undoubtedly boost market expansion.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-wise Insights

Which is the most Popular Application of Radiopharmaceuticals?

The Oncology Segment to Drive the Radiopharmaceuticals Market

The increasing prevalence of cancer and cardiovascular disorders such as coronary heart disease and heart failure throughout the world is providing a boost to market expansion. Increasing incidence of lifestyle disorders, obesity, and tumours caused by poor behaviours among the elderly are the primary forces driving up demand for radiopharmaceuticals. According to Future Market Insights, Inc increased instances of breast cancer, lung cancer, and prostate cancer will drive sector growth.

The increasing use of nuclear medicine in cancer and cardiology is the primary driver of market expansion. According to the American Cancer Society, 1.9 million new cancer cases will be recorded in 2021, and about 608,570 people will die from cancer in the United States. With the number of cancer cases increasing, healthcare experts are creating innovative new approaches to produce nuclear medicine for therapy. Rapid adoption of sophisticated radiopharmaceutical methods for cancer treatment will drive growth.

Radiopharmaceuticals play an important role in cancer diagnosis and treatment by improving understanding of disease stages. According to Future Market Insights, the rising use of nuclear medicine in cancer will account for more than 50% of the worldwide market value by 2032.

The Start-Up Ecosystem: How key Players are opening Frontiers for Future Growth?

Start-ups and their innovations are driving some of the most recent advances in the radiopharmaceuticals sector. Radiopharmaceuticals gives the consumer a precise diagnosis and to highlight some of the companies. Let's have a look at some of the primary areas of innovation in this industry:

  • Theragnostics, a British firm, creates radiopharmaceuticals based on fluorine-18. The primary medicine of the start-up, THG-008, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It assists in the imaging of head and neck cancer as well as brain cancer. THG-009, an iodine rPARPi, is also being developed by the company.
  • Navigo Proteins is a German business that creates innovative radio-conjugates. Affilin is a firm that creates artificial proteins that preferentially bind antigens and radio conjugates. This is accomplished by combining target-binding Affilin molecules with isotope-loaded chelators. The isotope-to-carrier ratios in the molecules are uniform. Researchers can fine-tune radio conjugates for theranostics by optimising the loaded radionuclide and the conjugate's specific half-life. In addition, the company is working on precision capture and precision targeting technologies, such as antibody purification and cellular treatment.
  • Naogen Pharma, a French firm, is developing rubidium-82 generators for CAD diagnosis. The company produces Rubidium-82 radionuclide using a strontium-82/rubidium-82 infuser and a strontium-82/rubidium-82 generator. This is directly connected to the veins of patients. The equipment, together with a positron emission tomography (PET) system, can be installed on the patient's bed. In addition, the firm offers PET scanning, cardiac ischemia detection, and other services.

Who are the Leading Players in the Radiopharmaceuticals Market?

According to Future Market Insights, market consolidation has resulted from intense rivalry among top competitors. The top five market participants are Siemens AG, G E Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler.

These top five players account for over 90% of the worldwide market share. The leading players' winning methods include providing innovative technology and nuclear medications for therapy.

Leading firms like as GE Healthcare and Siemens Healthcare are working on providing innovative product-based innovations, pharmaceutical services, and IT-based solutions in order to preserve their industry leadership.

Recent Developments:

  • In March 2021, Aktis Oncology, a biotechnology firm developing a unique class of targeted radiopharmaceuticals to treat a wide spectrum of solid tumour cancer patients, reported the completion of a solid tumour series.
  • In November 2020, Fusion Pharmaceuticals, a top Canadian radiopharmaceuticals business, announced cooperation with Anglo-Swedish Pharma giant AstraZeneca to commercialise and develop next-generation alpha emitting radiopharmaceuticals and combination treatments for cancer therapy.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 4.3% from 2022 to 2032

Market Value in 2022

US$ 6.2 Billion

Market Value in 2032

US$ 9.5 Billion

Base Year for Estimation

2021

Historical Data

2016 to 2021

Forecast Period

2022 to 2032

Quantitative Units

Revenue in US$ Million and CAGR from 2022 to 2032

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Radioisotope
  • Application
  • Source
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • Asia Pacific
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • United States
  • Canada
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Nordic
  • BENELUX
  • Russia
  • Poland
  • China
  • India
  • Australia & New Zealand
  • ASEAN
  • Gulf Cooperation Council
  • South Africa
  • Turkey

Key Companies Profiled

  • Siemens AG
  • Positron Corporation
  • Novartis (Advanced Accelerator Applications)
  • Curium
  • GE Healthcare
  • Lantheus Holdings Inc.
  • Sotera Health LLC (Nordion Inc.)
  • Bayer AG
  • Eckert & Ziegler

Customization & Pricing

Available upon Request

Key Segments Covered in the Radiopharmaceuticals Industry Analysis

Radiopharmaceuticals Market by Radioisotope Type:

  • Technetium-99
  • Fluorine-18
  • Iodine-131
  • Leutetium-177
  • Yttrium-90
  • Gallium-68
  • Gallium-67
  • Rubidium-82
  • Iodine-123
  • Iodine-125
  • Indium-111
  • Others

Radiopharmaceuticals Market by Application:

  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Neurology
  • Nephrology
  • Others

Radiopharmaceuticals Market by Source:

  • Cyclotrons
  • Nuclear Reactors

Radiopharmaceuticals Market by End User:

  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory Surgical Centers
  • Cancer Research Institute

Radiopharmaceuticals Market by Region:

  • North America Radiopharmaceuticals Market
  • Latin America Radiopharmaceuticals Market
  • Western Europe Radiopharmaceuticals Market
  • Eastern Europe Radiopharmaceuticals Market
  • APEJ Radiopharmaceuticals Market
  • Japan Radiopharmaceuticals Market
  • Middle East & Africa Radiopharmaceuticals Market

Frequently Asked Questions

By 2022-end, sales of radiopharmaceuticals closed at a value of US$ 6.2 Billion.

From 2016 to 2021, radiopharmaceuticals demand expanded at a CAGR of 3.8%

From 2022 to 2032, radiopharmaceuticals sales are expected to flourish at a CAGR of 4.3%

By 2032, the market value of radiopharmaceuticals expected to reach US$ 9.5 Billion

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Global Market Share Analysis

    1.3. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Macro-Economic Factors

        3.1.1. Increasing healthcare expenditure as a percentage of GDP

        3.1.2. Rise in Aging population

    3.2. Forecast Factors - Relevance & Impact

        3.2.1. Increasing Installed base for PET and SPECT Scanners

        3.2.2. Increasing Incidence of Cancer

        3.2.3. Increasing Diagnosis Rate

    3.3. Market Dynamics

        3.3.1. Opportunity Analysis

        3.3.2. Drivers

        3.3.3. Restraints

        3.3.4. Trends

4. Market Context

    4.1. Reimbursement Scenario

    4.2. Key Regulations

    4.3. Value Chain Analysis

5. Global Market Demand (Size in US$ Mn) Analysis 2016-2021 and Forecast, 2022-2032

    5.1. Historical Market Value (US$ Mn) Analysis, 2016-2021

    5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

    5.3. Market Value Growth Comparison

6. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Radioisotope

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Mn) Analysis By Radioisotope, 2016-2021

    6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Radioisotope, 2022-2032

        6.3.1. Technetium-99

        6.3.2. Fluorine-18

        6.3.3. Iodine-131

        6.3.4. Leutetium-177

        6.3.5. Yttrium-90

        6.3.6. Gallium-68

        6.3.7. Gallium-67

        6.3.8. Rubidium-82

        6.3.9. Iodine-123

        6.3.10. Iodine-125

        6.3.11. Indium-111

        6.3.12. Others

    6.4. Market Attractiveness Analysis By Radioisotope

7. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Application

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Application, 2016-2021

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2032

        7.3.1. Oncology

        7.3.2. Cardiology

        7.3.3. Gastroenterology

        7.3.4. Neuroendocrinology

        7.3.5. Neurology

        7.3.6. Nephrology

        7.3.7. Others

    7.4. Market Attractiveness Analysis By Application

8. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Source

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Source, 2016-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2022-2032

        8.3.1. Cyclotrons

        8.3.2. Nuclear Reactors

    8.4. Market Attractiveness Analysis By Source

9. Global Market Analysis 2016-2021 and Forecast 2022-2032, by End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032

        9.3.1. Hospitals

        9.3.2. Diagnostic Imaging Centers

        9.3.3. Ambulatory Surgical Centers

        9.3.4. Cancer Research Institute

    9.4. Market Attractiveness Analysis By End User

10. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Region

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Western Europe

        10.3.4. Eastern Europe

        10.3.5. APEJ

        10.3.6. Japan

        10.3.7. MEA

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2016-2021 and Forecast 2022-2032

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Radioisotope

        11.3.3. By Application

        11.3.4. By Source

        11.3.5. By End User

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Radioisotope

        11.4.3. By Application

        11.4.4. By Source

        11.4.5. By End User

12. Latin America Market Analysis 2016-2021 and Forecast 2022-2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Rest of Latin America

        12.3.2. By Radioisotope

        12.3.3. By Application

        12.3.4. By Source

        12.3.5. By End User

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Radioisotope

        12.4.3. By Application

        12.4.4. By Source

        12.4.5. By End User

13. Western Europe Market Analysis 2016-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. U.K

            13.3.1.3. France

            13.3.1.4. Spain

            13.3.1.5. Italy

            13.3.1.6. Nordic Countries

            13.3.1.7. Benelux

            13.3.1.8. Rest of Western Europe

        13.3.2. By Radioisotope

        13.3.3. By Application

        13.3.4. By Source

        13.3.5. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Radioisotope

        13.4.3. By Application

        13.4.4. By Source

        13.4.5. By End User

14. Eastern Europe Market Analysis 2016-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032

        14.3.1. By Country

            14.3.1.1. Russia

            14.3.1.2. Poland

            14.3.1.3. Rest of EE

        14.3.2. By Radioisotope

        14.3.3. By Application

        14.3.4. By Source

        14.3.5. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Radioisotope

        14.4.3. By Application

        14.4.4. By Source

        14.4.5. By End User

15. APEJ Market Analysis 2016-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. India

            15.3.1.3. Australia & New Zealand

            15.3.1.4. ASEAN

            15.3.1.5. Rest of APEJ

        15.3.2. By Radioisotope

        15.3.3. By Application

        15.3.4. By Source

        15.3.5. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Radioisotope

        15.4.3. By Application

        15.4.4. By Source

        15.4.5. By End User

16. Japan Market Analysis 2016-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032

        16.3.1. By Radioisotope

        16.3.2. By Application

        16.3.3. By Source

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Radioisotope

        16.4.2. By Application

        16.4.3. By Source

        16.4.4. By End User

17. Middle East and Africa Market Analysis 2016-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Rest of MEA

        17.3.2. By Radioisotope

        17.3.3. By Application

        17.3.4. By Source

        17.3.5. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Radioisotope

        17.4.3. By Application

        17.4.4. By Source

        17.4.5. By End User

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep Dive

        18.3.1. Siemens AG (Siemens Healthineers)

            18.3.1.1. Overview

            18.3.1.2. Service Portfolio

            18.3.1.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.1.4. Sales Footprint

            18.3.1.5. Strategy Overview

                18.3.1.5.1. Marketing Strategy

                18.3.1.5.2. Service Strategy

                18.3.1.5.3. Channel Strategy

        18.3.2. Positron Corporation

            18.3.2.1. Overview

            18.3.2.2. Service Portfolio

            18.3.2.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.2.4. Sales Footprint

            18.3.2.5. Strategy Overview

                18.3.2.5.1. Marketing Strategy

                18.3.2.5.2. Service Strategy

                18.3.2.5.3. Channel Strategy

        18.3.3. Novartis (Advanced Accelerator Applications)

            18.3.3.1. Overview

            18.3.3.2. Service Portfolio

            18.3.3.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.3.4. Sales Footprint

            18.3.3.5. Strategy Overview

                18.3.3.5.1. Marketing Strategy

                18.3.3.5.2. Service Strategy

                18.3.3.5.3. Channel Strategy

        18.3.4. Curium

            18.3.4.1. Overview

            18.3.4.2. Service Portfolio

            18.3.4.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.4.4. Sales Footprint

            18.3.4.5. Strategy Overview

                18.3.4.5.1. Marketing Strategy

                18.3.4.5.2. Service Strategy

                18.3.4.5.3. Channel Strategy

        18.3.5. GE Healthcare

            18.3.5.1. Overview

            18.3.5.2. Service Portfolio

            18.3.5.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.5.4. Sales Footprint

            18.3.5.5. Strategy Overview

                18.3.5.5.1. Marketing Strategy

                18.3.5.5.2. Service Strategy

                18.3.5.5.3. Channel Strategy

        18.3.6. Lantheus Holdings, Inc.

            18.3.6.1. Overview

            18.3.6.2. Service Portfolio

            18.3.6.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.6.4. Sales Footprint

            18.3.6.5. Strategy Overview

                18.3.6.5.1. Marketing Strategy

                18.3.6.5.2. Service Strategy

                18.3.6.5.3. Channel Strategy

        18.3.7. Sotera Health LLC (Nordion, Inc.)

            18.3.7.1. Overview

            18.3.7.2. Service Portfolio

            18.3.7.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.7.4. Sales Footprint

            18.3.7.5. Strategy Overview

                18.3.7.5.1. Marketing Strategy

                18.3.7.5.2. Service Strategy

                18.3.7.5.3. Channel Strategy

        18.3.8. Bayer AG

            18.3.8.1. Overview

            18.3.8.2. Service Portfolio

            18.3.8.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.8.4. Sales Footprint

            18.3.8.5. Strategy Overview

                18.3.8.5.1. Marketing Strategy

                18.3.8.5.2. Service Strategy

                18.3.8.5.3. Channel Strategy

        18.3.9. Eckert & Ziegler

            18.3.9.1. Overview

            18.3.9.2. Service Portfolio

            18.3.9.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.9.4. Sales Footprint

            18.3.9.5. Strategy Overview

                18.3.9.5.1. Marketing Strategy

                18.3.9.5.2. Service Strategy

                18.3.9.5.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value (US$ Mn) Growth Comparison

Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Radioisotope

Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Application

Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Source

Table 05: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By End User

Table 06: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Region

Table 07: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country

Table 08: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 09: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 10: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 11: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Table 12: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country

Table 13: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 14: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 15: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 16: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Table 17: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country

Table 18: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 19: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 20: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 21: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Table 22: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country

Table 23: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 24: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 25: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 26: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Table 27: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country

Table 28: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 29: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 30: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 31: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Table 32: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 33: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 34: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 35: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Table 36: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country

Table 37: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope

Table 38: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application

Table 39: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source

Table 40: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Revenue Share by Radioisotope, 2021E & 2031F

Figure 02: Global Market Revenue Share by Application, 2021E & 2031F

Figure 03: Global Market Revenue Share by Source, 2021E & 2031F

Figure 04: Global Market Revenue Share by End User, 2021E & 2031F

Figure 05: Global Market Revenue Share by Region, 2021E & 2031F

Figure 06: Market Value Analysis and Forecast 2021 – 2031 (US$ Mn)

Figure 07: Market Value (US$ Mn), 2016 – 2020

Figure 08: Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 09: Comparison February 2017 and October 2021, Y-o-Y Forecast

Figure 10: Global Market Share Analysis (%), By Radioisotope, 2021 & 2031

Figure 11: Global Market Y-o-Y Analysis (%), By Radioisotope, 2022-2032

Figure 12: Global Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 13: Global Market Share Analysis (%), By Application, 2021 & 2031

Figure 14: Global Market Y-o-Y Analysis (%), By Application, 2022-2032

Figure 15: Global Market Attractiveness Analysis by Application, 2022-2032

Figure 16: Global Market Share Analysis (%), By Source, 2021 & 2031

Figure 17: Global Market Y-o-Y Analysis (%), By Source, 2022-2032

Figure 18: Global Market Attractiveness Analysis by Source, 2022-2032

Figure 19: Global Market Share Analysis (%), By End User, 2021 & 2031

Figure 20: Global Market Y-o-Y Analysis (%), By End User, 2022-2032

Figure 21: Global Market Attractiveness Analysis by End User, 2022-2032

Figure 22: Global Market Share Analysis (%), By Region, 2021 & 2031

Figure 23: Global Market Y-o-Y Analysis (%), By Region, 2022-2032

Figure 24: Global Market Attractiveness Analysis by Region, 2022-2032

Figure 25: North America Market Value Share, By Radioisotope (2022 E)

Figure 26: North America Market Value Share, By Application (2022 E)

Figure 27: North America Market Value Share, By Source (2022 E)

Figure 28: North America Market Value Share, By End User (2022 E)

Figure 29: North America Market Value Share, By Country (2022 E)

Figure 30: North America Market Value Analysis (US$ Mn), 2016-2021

Figure 31: North America Market Value Forecast (US$ Mn), 2022-2032

Figure 32: North America Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 33: North America Market Attractiveness Analysis by Application, 2022-2032

Figure 34: North America Market Attractiveness Analysis by Source, 2022-2032

Figure 35: North America Market Attractiveness Analysis by End User, 2022-2032

Figure 36: North America Market Attractiveness Analysis by Region, 2022-2032

Figure 37: Latin America Market Value Share, By Radioisotope (2022 E)

Figure 38: Latin America Market Value Share, By Application (2022 E)

Figure 39: Latin America Market Value Share, By Source (2022 E)

Figure 40: Latin America Market Value Share, By End User (2022 E)

Figure 41: Latin America Market Value Share, By Country (2022 E)

Figure 42: Latin America Market Value Analysis (US$ Mn),2016-2021

Figure 43: Latin America Market Value Forecast (US$ Mn), 2022-2032

Figure 44: Latin America Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 45: Latin America Market Attractiveness Analysis by Application, 2022-2032

Figure 46: Latin America Market Attractiveness Analysis by Source, 2022-2032

Figure 47: Latin America Market Attractiveness Analysis by End User, 2022-2032

Figure 48: Latin America Market Attractiveness Analysis by Region, 2022-2032

Figure 49: Western Europe Market Value Share, By Radioisotope (2022 E)

Figure 50: Western Europe Market Value Share, By Application (2022 E)

Figure 51: Western Europe Market Value Share, By Source (2022 E)

Figure 52: Western Europe Market Value Share, By End User (2022 E)

Figure 53: Western Europe Market Value Share, By Country (2022 E)

Figure 54: Western Europe Market Value Analysis (US$ Mn),2016-2021

Figure 55: Western Europe Market Value Forecast (US$ Mn), 2022-2032

Figure 56: Western Europe Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 57: Western Europe Market Attractiveness Analysis by Application, 2022-2032

Figure 58: Western Europe Market Attractiveness Analysis by Source, 2022-2032

Figure 59: Western Europe Market Attractiveness Analysis by End User, 2022-2032

Figure 60: Western Europe Market Attractiveness Analysis by Region, 2022-2032

Figure 61: Eastern Europe Market Value Share, By Radioisotope (2022 E)

Figure 62: Eastern Europe Market Value Share, By Application (2022 E)

Figure 63: Eastern Europe Market Value Share, By Source (2022 E)

Figure 64: Eastern Europe Market Value Share, By End User (2022 E)

Figure 65: Eastern Europe Market Value Share, By Country (2022 E)

Figure 66: Eastern Europe Market Value Analysis (US$ Mn),2016-2021

Figure 67: Eastern Europe Market Value Forecast (US$ Mn), 2022-2032

Figure 68: Eastern Europe Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 69: Eastern Europe Market Attractiveness Analysis by Application, 2022-2032

Figure 70: Eastern Europe Market Attractiveness Analysis by Source, 2022-2032

Figure 71: Eastern Europe Market Attractiveness Analysis by End User, 2022-2032

Figure 72: Eastern Europe Market Attractiveness Analysis by Region, 2022-2032

Figure 73: APEJ Market Value Share, By Radioisotope (2022 E)

Figure 74: APEJ Market Value Share, By Application (2022 E)

Figure 75: APEJ Market Value Share, By Source (2022 E)

Figure 76: APEJ Market Value Share, By End User (2022 E)

Figure 77: APEJ Market Value Share, By Country (2022 E)

Figure 78: APEJ Market Value Analysis (US$ Mn),2016-2021

Figure 79: APEJ Market Value Forecast (US$ Mn), 2022-2032

Figure 80: APEJ Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 81: APEJ Market Attractiveness Analysis by Application, 2022-2032

Figure 82: APEJ Market Attractiveness Analysis by Source, 2022-2032

Figure 83: APEJ Market Attractiveness Analysis by End User, 2022-2032

Figure 84: APEJ Market Attractiveness Analysis by Region, 2022-2032

Figure 85: Japan Market Value Share, By Radioisotope (2022 E)

Figure 86: Japan Market Value Share, By Application (2022 E)

Figure 87: Japan Market Value Share, By Source (2022 E)

Figure 88: Japan Market Value Share, By End User (2022 E)

Figure 89: Japan Market Value Analysis (US$ Mn),2016-2021

Figure 90: Japan Market Value Forecast (US$ Mn), 2022-2032

Figure 91: Japan Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 92: Japan Market Attractiveness Analysis by Application, 2022-2032

Figure 93: Japan Market Attractiveness Analysis by Source, 2022-2032

Figure 94: Japan Market Attractiveness Analysis by End User, 2022-2032

Figure 95: MEA Market Value Share, By Radioisotope (2022 E)

Figure 96: MEA Market Value Share, By Application (2022 E)

Figure 97: MEA Market Value Share, By Source (2022 E)

Figure 98: MEA Market Value Share, By End User (2022 E)

Figure 99: MEA Market Value Share, By Country (2022 E)

Figure 100: MEA Market Value Analysis (US$ Mn),2016-2021

Figure 101: MEA Market Value Forecast (US$ Mn), 2022-2032

Figure 102: MEA Market Attractiveness Analysis by Radioisotope, 2022-2032

Figure 103: MEA Market Attractiveness Analysis by Application, 2022-2032

Figure 104: MEA Market Attractiveness Analysis by Source, 2022-2032

Figure 105: MEA Market Attractiveness Analysis by End User, 2022-2032

Figure 106: MEA Market Attractiveness Analysis by Region, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Chemicals & Materials

Pharmaceuticals Preservative Market

Published : October 2018

Chemicals & Materials

Pharmaceuticals Grade Sodium Bicarbonate Market

Published : March 2018

Healthcare

Oxytocic Pharmaceuticals Market

Published : July 2021

Healthcare

Topical Antibiotic Pharmaceuticals Market

Published : April 2016

Google translate

Radiopharmaceuticals Market